What would you like first: the good news or the bad news? Let me start with the bad. Life expectancy among patients in the U.S. with thyroid cancer lags behind that in Korea. In fact, the vast majority of patients diagnosed with thyroid cancer in Korea are cured of that illness, a statement I can’t as easily make about the U.S.
The good news? Life expectancy among patients in the U.S. with thyroid cancer lags behind that in Korea.
Okay, I kind of pulled a fast one on you. I tried to mislead you into thinking it is bad when cancer patients in another country out-live cancer patients in the U.S. On the surface, living longer after experiencing a cancer diagnosis seems to be a good thing. All else equal, it is better to survive cancer than to die from it.
But all else is far from equal when it comes to thyroid cancer in the U.S. versus Korea. (To read the rest of this article, please visit Forbes.)
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.